Literature DB >> 6290516

Simultaneous determination of thioridazine and its S-oxidized and N-demethylated metabolites using high-performance liquid-chromatography on radially compressed silica.

C D Kilts, K S Patrick, G R Breese, R B Mailman.   

Abstract

A method for simultaneously quantifying thioridazine, northioridazine, thioridazine-2-sulfoxide, thioridazine-2-sulfone and thioridazine-5-oxide in serum and plasma is described. Following solvent extraction these compounds were separated by high-performance liquid chromatography on radially compressed silica gel and detected by UV absorbance at 254 nm. Chromatography time is less than 7 min. The relative retention of these compounds as a function of the methanol and methylamine content of the mobile phase is discussed. Practical limits of detection, based upon on assayed plasma or serum volume of 1 ml, were 20 ng/ml for thioridazine-5-oxide and 10 ng/ml for the other compounds. The coefficient of variation for all compounds was less than 13%. The method is compared with more conventional high-performance liqiud chromatographic and gas chromatographic methodology.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6290516     DOI: 10.1016/s0378-4347(00)81862-9

Source DB:  PubMed          Journal:  J Chromatogr


  3 in total

1.  Clinical implications of slow sulphoxidation of thioridazine in a poor metabolizer of the debrisoquine type.

Authors:  J W Meyer; B Woggon; P Baumann; U A Meyer
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

2.  HPLC with electrochemical detection to measure chlorpromazine, thioridazine and metabolites in human brain.

Authors:  C N Svendsen; E D Bird
Journal:  Psychopharmacology (Berl)       Date:  1986       Impact factor: 4.530

3.  Synthesis and properties of haptens for the development of radioimmunoassays for thioridazine, mesoridazine, and sulforidazine.

Authors:  B S Chakraborty; M S Sardessai; T J Jaworski; K K Midha; E M Hawes
Journal:  Pharm Res       Date:  1987-06       Impact factor: 4.200

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.